StreetInsider.com News Articles

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Tue, 07 Jan 2025 11:19:00 -0400

LUND, Sweden, Jan. 7, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced that management will attend the 43^rd Annual J.P. Morgan Healthcare Conference. If you are interested in a meeting, please contact Hansa Biopharma at ir@hansabiopharma.com.

The Company has achieved several key milestones in the last 12-months across its three key therapeutic areas: Autoimmune, Gene Therapy and Transplantation.

In Autoimmune, the company announced positive data from the 15-HMedIdeS-09 Phase 2 trial in Guillain Barre Syndrome (GBS)

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Tue, 07 Jan 2025 11:19:00 -0400

The Company has achieved several key milestones in the last 12-months across its three key therapeutic areas: Autoimmune, Gene Therapy and Transplantation.

In Autoimmune, the company announced positive data from the 15-HMedIdeS-09 Phase 2 trial in Guillain Barre Syndrome (GBS)

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Tue, 07 Jan 2025 11:19:00 -0400

The Company has achieved several key milestones in the last 12-months across its three key therapeutic areas: Autoimmune, Gene Therapy and Transplantation.

In Autoimmune, the company announced positive data from the 15-HMedIdeS-09 Phase 2 trial in Guillain Barre Syndrome (GBS)

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Tue, 07 Jan 2025 11:19:00 -0400

The Company has achieved several key milestones in the last 12-months across its three key therapeutic areas: Autoimmune, Gene Therapy and Transplantation.

In Autoimmune, the company announced positive data from the 15-HMedIdeS-09 Phase 2 trial in Guillain Barre Syndrome (GBS)

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Tue, 07 Jan 2025 11:19:00 -0400

The Company has achieved several key milestones in the last 12-months across its three key therapeutic areas: Autoimmune, Gene Therapy and Transplantation.

In Autoimmune, the company announced positive data from the 15-HMedIdeS-09 Phase 2 trial in Guillain Barre Syndrome (GBS)

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Tue, 07 Jan 2025 11:19:00 -0400

The Company has achieved several key milestones in the last 12-months across its three key therapeutic areas: Autoimmune, Gene Therapy and Transplantation.

In Autoimmune, the company announced positive data from the 15-HMedIdeS-09 Phase 2 trial in Guillain Barre Syndrome (GBS)

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Tue, 07 Jan 2025 11:19:00 -0400

The Company has achieved several key milestones in the last 12-months across its three key therapeutic areas: Autoimmune, Gene Therapy and Transplantation.

In Autoimmune, the company announced positive data from the 15-HMedIdeS-09 Phase 2 trial in Guillain Barre Syndrome (GBS)

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Tue, 07 Jan 2025 11:19:00 -0400

The Company has achieved several key milestones in the last 12-months across its three key therapeutic areas: Autoimmune, Gene Therapy and Transplantation.

In Autoimmune, the company announced positive data from the 15-HMedIdeS-09 Phase 2 trial in Guillain Barre Syndrome (GBS)

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Tue, 07 Jan 2025 11:19:00 -0400

The Company has achieved several key milestones in the last 12-months across its three key therapeutic areas: Autoimmune, Gene Therapy and Transplantation.

In Autoimmune, the company announced positive data from the 15-HMedIdeS-09 Phase 2 trial in Guillain Barre Syndrome (GBS)

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Tue, 07 Jan 2025 11:19:00 -0400

The Company has achieved several key milestones in the last 12-months across its three key therapeutic areas: Autoimmune, Gene Therapy and Transplantation.

In Autoimmune, the company announced positive data from the 15-HMedIdeS-09 Phase 2 trial in Guillain Barre Syndrome (GBS)

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Tue, 07 Jan 2025 11:19:00 -0400

The Company has achieved several key milestones in the last 12-months across its three key therapeutic areas: Autoimmune, Gene Therapy and Transplantation.

In Autoimmune, the company announced positive data from the 15-HMedIdeS-09 Phase 2 trial in Guillain Barre Syndrome (GBS)

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Tue, 07 Jan 2025 11:19:00 -0400

The Company has achieved several key milestones in the last 12-months across its three key therapeutic areas: Autoimmune, Gene Therapy and Transplantation.

In Autoimmune, the company announced positive data from the 15-HMedIdeS-09 Phase 2 trial in Guillain Barre Syndrome (GBS)

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Tue, 07 Jan 2025 11:19:00 -0400

The Company has achieved several key milestones in the last 12-months across its three key therapeutic areas: Autoimmune, Gene Therapy and Transplantation.

In Autoimmune, the company announced positive data from the 15-HMedIdeS-09 Phase 2 trial in Guillain Barre Syndrome (GBS)

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Tue, 07 Jan 2025 11:19:00 -0400

The Company has achieved several key milestones in the last 12-months across its three key therapeutic areas: Autoimmune, Gene Therapy and Transplantation.

In Autoimmune, the company announced positive data from the 15-HMedIdeS-09 Phase 2 trial in Guillain Barre Syndrome (GBS)

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Tue, 07 Jan 2025 11:19:00 -0400

The Company has achieved several key milestones in the last 12-months across its three key therapeutic areas: Autoimmune, Gene Therapy and Transplantation.

In Autoimmune, the company announced positive data from the 15-HMedIdeS-09 Phase 2 trial in Guillain Barre Syndrome (GBS)

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Tue, 07 Jan 2025 11:19:00 -0400

The Company has achieved several key milestones in the last 12-months across its three key therapeutic areas: Autoimmune, Gene Therapy and Transplantation.

In Autoimmune, the company announced positive data from the 15-HMedIdeS-09 Phase 2 trial in Guillain Barre Syndrome (GBS)

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Tue, 07 Jan 2025 11:19:00 -0400

The Company has achieved several key milestones in the last 12-months across its three key therapeutic areas: Autoimmune, Gene Therapy and Transplantation.

In Autoimmune, the company announced positive data from the 15-HMedIdeS-09 Phase 2 trial in Guillain Barre Syndrome (GBS)

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Tue, 07 Jan 2025 11:19:00 -0400

The Company has achieved several key milestones in the last 12-months across its three key therapeutic areas: Autoimmune, Gene Therapy and Transplantation.

In Autoimmune, the company announced positive data from the 15-HMedIdeS-09 Phase 2 trial in Guillain Barre Syndrome (GBS)

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Tue, 07 Jan 2025 11:19:00 -0400

The Company has achieved several key milestones in the last 12-months across its three key therapeutic areas: Autoimmune, Gene Therapy and Transplantation.

In Autoimmune, the company announced positive data from the 15-HMedIdeS-09 Phase 2 trial in Guillain Barre Syndrome (GBS)

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Tue, 07 Jan 2025 11:19:00 -0400

The Company has achieved several key milestones in the last 12-months across its three key therapeutic areas: Autoimmune, Gene Therapy and Transplantation.

In Autoimmune, the company announced positive data from the 15-HMedIdeS-09 Phase 2 trial in Guillain Barre Syndrome (GBS)

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Tue, 07 Jan 2025 11:19:00 -0400

The Company has achieved several key milestones in the last 12-months across its three key therapeutic areas: Autoimmune, Gene Therapy and Transplantation.

In Autoimmune, the company announced positive data from the 15-HMedIdeS-09 Phase 2 trial in Guillain Barre Syndrome (GBS)

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Tue, 07 Jan 2025 11:19:00 -0400

The Company has achieved several key milestones in the last 12-months across its three key therapeutic areas: Autoimmune, Gene Therapy and Transplantation.

In Autoimmune, the company announced positive data from the 15-HMedIdeS-09 Phase 2 trial in Guillain Barre Syndrome (GBS)

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Tue, 07 Jan 2025 11:19:00 -0400

The Company has achieved several key milestones in the last 12-months across its three key therapeutic areas: Autoimmune, Gene Therapy and Transplantation.

In Autoimmune, the company announced positive data from the 15-HMedIdeS-09 Phase 2 trial in Guillain Barre Syndrome (GBS)

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Tue, 07 Jan 2025 11:19:00 -0400

The Company has achieved several key milestones in the last 12-months across its three key therapeutic areas: Autoimmune, Gene Therapy and Transplantation.

In Autoimmune, the company announced positive data from the 15-HMedIdeS-09 Phase 2 trial in Guillain Barre Syndrome (GBS)

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Tue, 07 Jan 2025 11:19:00 -0400

The Company has achieved several key milestones in the last 12-months across its three key therapeutic areas: Autoimmune, Gene Therapy and Transplantation.

In Autoimmune, the company announced positive data from the 15-HMedIdeS-09 Phase 2 trial in Guillain Barre Syndrome (GBS)